Acelrx Pharmaceuticals Inc., of Redwood City, Calif., which launched Dsuvia, a sublingual 30-mcg tablet version of sufentanil, in February, recorded a net loss of $13.7 million, or 17 cents per basic and diluted share for the first quarter of 2019, compared to $11.6 million, or 23 cents per basic and diluted share, for the first quarter of 2018. The company closed the period with cash, cash equivalents and short-term investments of $90.2 million.